78318-60-2

Basic information

• Product Name: 3-(2-HYDROXY-ETHOXYMETHYL)-2,5,9-TRIMETHYL-FURO[3,2-G]CHROMEN-7-ONE
• Synonyms: 3-(2-HYDROXY-ETHOXYMETHYL)-2,5,9-TRIMETHYL-FURO[3,2-G]CHROMEN-7-ONE;4'-(2-HYDROXYETHOXY)METHYL-4,5',8-TRIMETHYLPSORALEN
• CAS NO: 78318-60-2
• Molecular Formula: C17H18O5
• Molecular Weight: 302.32
• Mol File: 78318-60-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(2-HYDROXY-ETHOXYMETHYL)-2,5,9-TRIMETHYL-FURO[3,2-G]CHROMEN-7-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-HYDROXY-ETHOXYMETHYL)-2,5,9-TRIMETHYL-FURO[3,2-G]CHROMEN-7-ONE(78318-60-2)
• EPA Substance Registry System: 3-(2-HYDROXY-ETHOXYMETHYL)-2,5,9-TRIMETHYL-FURO[3,2-G]CHROMEN-7-ONE(78318-60-2)

Safety Data

• Hazardous Substances Data: 78318-60-2(Hazardous Substances Data)

Upstream product

• 3902-71-4 trioxsalen 
• 62442-57-3 4'-chloromethyl-4,5',8-trimethylpsoralen 
• 107-21-1 ethylene glycol 

Relevant articles and documents

Design and Application of Mini-libraries of miRNA Probes for an Efficient and Versatile miRNA-mRNA Cross-linking

MicroRNAs constitute a class of endogenous, non-coding RNAs that influence various processes within the cell. By base-pairing to partially-complementary sites located in the 3’ untranslated region of target messenger RNAs, microRNAs participate in post-transcriptional regulation of the majority of human protein-coding genes. Their dysregulation has been related to many pathological processes and diseases. Thus, an in-depth understanding of the microRNA mechanisms of action is crucial. Here, we present a new concept of probe design to achieve an efficient and sequence-independent miRNA-mRNA cross-linking. The new strategy is based on the utilization of a controlled mixture of probes for a chosen miRNA, in which a trioxsalen moiety is introduced at the N4-position of a selected cytidine through short oligoethylene glycol-based linkers. In vitro photo-cross-linking experiments with mini-libraries of probes for microRNAs of interest showed variable cross-linking efficiencies, demonstrating a general applicability of the presented approach.

Methods and devices for the removal of psoralens from blood products

Methods and devices for the removal of psoralens and psoralen photoproducts from blood products are described. The methods include contacting a psoralen- and irradiation-treated blood product with a resin capable of adsorbing psoralens and psoralen photoproducts. The removal process is particularly suitable for use with platelet concentrates and plasma because the process does not have a significant adverse effect on clotting factor function. The methods and devices can be incorporated with apheresis systems and other devices and procedures currently used to process blood products for transfusion.

Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens

Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.